|本期目录/Table of Contents|

[1]王乐民.静脉血栓的起源与发生[J].慢性病学杂志,2015,(04):405-411.
点击复制

静脉血栓的起源与发生(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2015年04期
页码:
405-411
栏目:
综述
出版日期:
2015-08-30

文章信息/Info

Title:
-
作者:
王乐民
同济大学附属同济医院心内科，上海 200065
Author(s):
-
关键词:
静脉血栓; 免疫细胞; 感染性验证; 血小板; 整合素
Keywords:
-
分类号:
R543.6
DOI:
-
摘要:
静脉血栓的起源与发生，是在免疫细胞平衡功能崩溃状态下，失去及时、有效清除胞内感染细胞/恶 变细胞的功能，静脉内发生的感染性炎症/非感染性炎症。活化的血小板、白细胞膜整合素受体β3、β2与 配体纤维蛋白原等免疫粘附性结合，在静脉内构建可逆性结合的丝状筛网结构，似静脉生物滤器，承担机 体的代偿性物理防御，其功能是阻止静脉下端的胞内感染细胞/恶性肿瘤细胞回流全身，当以红细胞为主的 血细胞回流滞满生物滤器内，红色血栓形成。可逆性结合的丝状筛网结构，是在血流滞缓状态下完成的，快 速血流状态下，丝状筛网结构被是难以建立的。中性粒细胞膜整合素β2受体与配体Ⅹ结合，转化为Ⅹa，促 使纤维蛋白原转变为纤维蛋白，静脉生物滤器变得牢固。获得性、家族性静脉血栓的起源与形成机制是相 同的。免疫细胞平衡功能健全者，机体的胞内感染细胞/恶变细胞被及时、有效清除，机体不需要建立静脉 生物滤器这样的物理屏障，因此，也不可能发生急性静脉血栓事件。
Abstract:
-

参考文献/References:

[1]Cardiovascular Disease Educational and Research Trust, Cy? prus Cardiovascular Disease Educational and Research Trust, European Venous Forum,et al. Prevention and treatment of venous thromboembolism International Consensus Statement (guidelines according to scientific evidence)[J]．Int Angiol, 2006,25(2):101-161.
[2]Piazza G, GoldhaberSZ.Physician alerts to preventvenous thromboembolism[J]．J Thromb Thrombolysis,2010,30(1): 1-6.
[3]Guyatt GH,Akl EA,Crowther M,et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines[J]．Chest,2012,141(2Suppl): 7S-47S.
[4] Shackford SR, Rogers FB, Terrien CM,etal.A10-year analysis of venous thromboembolism on the surgical service: the effect of practice guidelines for prophylaxis [J]．Surgery, 2008,144(1):3-11.
[5]Wang L, Gong Z, Jiang J,et al. Confusion of wide thrombo? lytic time window for acute pulmonary embolism: mass spec? trographic analysis for thrombus proteins [J]．Am J Respir CritCare Med,2011,184(1):145-146.
[6] GiancottiFG,RuoslahtiE.Integrin signaling[J]．Science, 1999,285(5430):1028-1032.
[7]Takada Y, Ye X, Simon S. The integrins[J]．Genome Bi? ol,2007,8(5):215.
[8] Xiong JP, Stehle T, Diefenbach B,et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 [J]．Sci? ence,2001,294(5541):339-345.
[9] Humphries MJ.Integrin structure[J]．Biochem Soc Trans, 2000,28(4):311-339.
[10]Solovjov DA, Pluskota E, Plow EF. Distinct roles for the al? pha and beta subunits in the functions of integrin alphaMbeta2 [J]．J BiolChem,2005,280(2):1336-1345.
[11]Gerber DJ, Pereira P, Huang SY,et al. Expression of alpha v and beta3integrin chains on murine lymphocytes [J]．Proc NatlAcad SciU S A,1996,93(25):14698-14703.
[12]Lityńska A, Przyby?o M, Ksiazek D,et al. Differences of al? pha3beta1integrin glycans from different human bladder cell lines[J]．Acta Biochim Pol,2000,47(2):427-434.
[13]Wang LM, Duan QL, Yang F,et al. Activation of circulated immune cells and inflammatory immune adherence are in? volved in the whole process of acute venous thrombosis[J]． IntJ Clin Exp Med,2014,7(3):566-572.
[14]Wang LM, Duan QL, Yi XH,et al. Venous thromboembo? lism is a product in proliferation of cancer cells [J]．Int J Clin Exp Med,2014,7(5):1319-1323.
[15] Wang L, Gong Z, Liang A,et al. Compromised T-cell im? munity and virus-like structure in a patient with pulmonary hy? pertension[J]．Am J Respir Crit Care Med,2010,182(3): 434-435.
[16] Wang L, Zhang X, Duan Q,et al. Rod-like Bacteria and Re? current Venous Thromboembolism[J]．Am J Respir Crit Care Med,2012,186(7):696.
[17]Wang H, Wang C, Zhang L,et al. Analysis of the protein-protein interaction networks of differentially expressed genes in pulmonary embolism[J]．Mol Med Rep,2015,11(4):2527-2533.
[18]Wang H, Duan Q, Wang L,et al. Analysis on the pathogene? sis of symptomatic pulmonary embolism with human genomics [J]．IntJ Med Sci,2012,9(5):380-386.
[19]Lv W, Wang L, Duan Q,et al. Characteristics of the comple? ment system gene expression deficiency in patients with symp? tomatic pulmonary embolism [J]．Thromb Res,2013,132 (1):e54-57.
[20]Lv W, Duan Q, Wang L,etal.Gene expression levels ofcyto? kines in peripheral blood mononuclear cells from patients with pulmonary embolism[J]．Mol Med Rep,2013,7(4):1245-1250.
[21]Duan Q, Lv W, Wang L,et al. mRNA expression of interleu? kins and Th1/Th2imbalance in patients with pulmonary em? bolism[J]．MolMed Rep,2013,7(1):332-336.
[22] Xie Y, Duan Q, Wang L,et al. Genomic characteristics of ad? hesion molecules in patients with symptomatic pulmonary em? bolism[J]．MolMed Rep,2012,6(3):585-590.
[23]Lv W, Duan Q, Wang L,et al. Expression of B cell related genes in peripheral blood mononuclear cells of patients with symptomatic pulmonary embolism[J]．Mol Med Rep,2015, 11(3):2299-2305.
[24]Lv W, Yang M, Yang F,et al. Characterization of immune cell/molecule perforin mutations in a family with venous thromboembolism [J]．Int J Clin Exp Med, 2015. [Epub ahead ofprint]
[25]Smeeth L, Cook C, Thomas S,et al. Risk of deep vein throm? bosis and pulmonary embolism after acute infection in a com? munity setting[J]．Lancet,2006,367(9516):1075-1079.
[26]Clayton TC, Gaskin M, Meade TW. Recent respiratory infec? tion and risk of venous thromboembolism: case-control study through a general practice database [J]．Int J Epidemiol, 2011,40(3):819-827.
[27]Schmidt M, Horvath-Puho E, Thomsen RW,et al. Acute in? fections and venous thromboembolism [J]．J Intern Med, 2012,271(6):608-618.
[28] Xiang-Hua Y, Le-Min W, Ai-Bin L,et al. Severe acute re? spiratory syndrome and venous thromboembolism in multiple organs[J]．Am J Respir Crit Care Med,2010,182(3):436-437.
[29]Wang L, Song H, Gong Z,et al. Acute pulmonary embolism and dysfunction of CD3+ CD8+ T cell immunity[J]．Am J RespirCritCare Med,2011,184(11):1315.
[30] Song HM, Wang LM, Gong Z,et al. T cell-mediated im? mune deficiency or compromise in patients with CTEPH[J]． Am J RespirCritCare Med,2011,183(3):417-418.
[31]Duan QL, Gong Z, Song HM,et al. Symptomatic venous thromboembolism is a disease related to infection and immune dysfunction[J]．IntJ Med Sci,2012,9(6):453-461.
[32] Chew HK, Wun T, Harvey D,et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers[J]．Arch Int Med,2006,166:(4)458-464.
[33]Khorana AA, Liebman HA, White RH,et al. The risk of ve? nous thromboembolism in patients with cancer[J]．American Society ofClinicalOncology;CancerThromb,2008:240-248.
[34]Chew HK, Wun T, Harvey DJ,et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients[J]．J Clin Oncol,2007,25(1):70-76.
[35]Wun T, White RH. Epidemiology of cancer- related venous throm- boembolism [J]．Best Pract Res Clin Haematol, 2009,22(1):9-23.
[36]Blom JW, Doggen CJ, Osanto S,et al. Malignancies, pro-thrombotic mutations, and the risk of venous thrombosis [J]． JAMA,2005,293(6):715-722.
[37]Wang LM, Duan QL, Yi XH,et al. Venous thromboembo? lism is a product in proliferation of cancer cells [J]．Int J Clin Exp Med,2014,7(5):1319-1323.
[38]Duan Q, Wang L, Yang F,et al. Internal relationship between symptomatic venous thromboembolism and risk factors: up-regulation of integrin β1,β2andβ3levels[J]．Am J Transl Res,2015,7(3):624-631.
[39]Song Y, Yang F, Wang L,et al. Increased expressions of inte? grin subunit beta1, beta2 and beta3 in patients with venous thromboembolism: new markers for venous thromboembolism [J]．IntJ Clin Exp Med,2014,7(9):2578-2584.

备注/Memo

备注/Memo:
基金项目：国家十二五科技支撑计划（2011BAI11B00） 作者简介：王乐民，教授，博士生导师，主要从事静脉血 栓形成机制，心血管疾病康复的研究 通信作者：E-mail: wanglemin2003@163.com
更新日期/Last Update: 2015-08-25